Next Article in Journal
A New 3-Benzylchroman Derivative from Sappan Lignum (Caesalpinia sappan)
Next Article in Special Issue
Novel Strategies to Improve the Anticancer Action of 5-Fluorouracil by Using Drug Delivery Systems
Previous Article in Journal
Rigorous Biogenetic Network for a Group of Indole Alkaloids Derived from Strictosidine
Previous Article in Special Issue
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Molecules 2008, 13(8), 1897-1922; doi:10.3390/molecules13081897
Review

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review

1,* , 1
, 2
, 3
, 4
 and 5
1 Attikon University Hospital of Athens, 2nd Radiology Department, Radiation Therapy Unit, Medical School of Athens, Greece 2 University Hospital of Thrace, Radiation Therapy Unit, Alexandroupolis, Greece 3 Policlinic of Athens, Section of Pathology, Athens Greece 4 Saint Savvas Anticancer Institute of Athens, 1st Radiation Therapy Unit Athens Greece 5 Aretaieion University Hospital, 1st Radiology Department, Radiation Therapy Unit, Medical School of Athens, Greece
* Author to whom correspondence should be addressed.
Received: 30 May 2008 / Revised: 15 August 2008 / Accepted: 25 August 2008 / Published: 27 August 2008
(This article belongs to the Special Issue 5-Fluorouracil)
Download PDF [289 KB, uploaded 18 June 2014]

Abstract

Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas.
Keywords: Capecitabine; Xeloda; cancer treatment Capecitabine; Xeloda; cancer treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Koukourakis, G.V.; Kouloulias, V.; Koukourakis, M.J.; Zacharias, G.A.; Zabatis, H.; Kouvaris, J. Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review. Molecules 2008, 13, 1897-1922.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert